Marksans Pharma bags USFDA nod for Esomeprazole Magnesium Delayed Release Capsules

Esomeprazole is used to treat certain stomach and esophagus problems (such as acid reflux and ulcer).

Published On 2023-10-04 06:01 GMT   |   Update On 2023-10-04 06:01 GMT

Mumbai: Marksans Pharma Limited has announced that the Company has received final approval from US Food & Drugs Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg (OTC). 

This product is bioequivalent to the reference listed drug (RLD), Nexium 24 HR Delayed-Release Capsules, 20mg (OTC), of AstraZeneca Pharmaceuticals LP.

Esomeprazole is used to treat certain stomach and esophagus problems (such as acid reflux and ulcer). It works by decreasing the amount of acid your stomach makes. It relieves symptoms such as heartburn, difficulty swallowing, and cough. This medication helps heal acid damage to the stomach and esophagus, helps prevent ulcers and is expected to help prevent cancer of the esophagus. Esomeprazole belongs to a class of drugs known as proton pump inhibitors (PPIs).

Advertisement

The product will be manufactured at the Company's formulation manufacturing facility in Goa, India.

Read also: Marksans Pharma Mucus loosening drug Guaifenesin ER bags USFDA okay

Marksans Pharma Limited, headquartered in Mumbai, India, is engaged in Research, Manufacturing and marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities located in India, USA and UK are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Antidiabetic, Pain Management, Gastroenterological and Anti-allergies. The company is marketing these products globally.

Read also: Marksans Pharma bags USFDA nod for Acetaminophen, Ibuprofen Tablets

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News